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The occurrence and distribution of PHI-like immunoreactivity in the guinea pig gallbladder has been ana- 
lysed by radioimmunoassay and immunocytochemistry. Chromatography of gallbladder extracts by gel per- 
meation and high-performance liquid chromatography revealed that guinea pig PHI-like immunoreactivity 
is of a similar size to that of porcine PHI but may differ in its amino acid sequence. Immunocytochemistry 
showed PHI-immunoreactivity to be localised to nerves found predominantly in the ganglionated plexus 
and the mucosal plexus of the gallbladder. Pure natural porcine PHI induced a dose-dependent relaxation 
of the isolated guinea pig gallbladder muscle which was not blocked by antagonists to acetylcholine, cate- 
cholamines, histamine, and Shydroxytryptamine. PHI may thus be one of the local factors involved in con- 
trolling gallbladder function. 
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1. INTRODUCTION 
Peptide histidine isoleucine (PHI) is a 27 amino 
acid peptide isolated from porcine gut which shows 
considerable amino acid sequence similarities to 
members of the glucagon-secretin family of pep- 
tides [ 11. PHI immunoreactive (PHI-IR) material 
has been demonstrated in both gut [2,3], and brain 
[4] suggesting a possible physiological role as a 
neurotransmitter or neuromodulator. Indeed, PHI 
has recently also been purified from porcine brain 
and shown to be identical to the intestinal peptide 
151. 
PHI has a number of biological activities in 
common with VIP. Both peptides are potent 
stimulants of pancreatic secretion [6-91 and in- 
testinal secretion in several species [ 10-121. In ad- 
dition it has been shown that PHI can displace VIP 
label bound to membrane receptors from lung 
1131. However, unlike VIP, PHI is only a weak 
vasodilator [ 141. 
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Authors in [ 151 have recently reported the ex- 
istence of a number of regulatory peptides, present 
in nerves and mucosal endocrine cells of the guinea 
pig gall bladder. PHI has been shown to reduce 
basal bilirubin and bile acid output in man [ 161 and 
to decrease basal gallbladder pressure and fluid 
reabsorption in the guinea pig [17]. PHI may thus 
be an additional local peptide involved in gallblad- 
der function. We have, therefore, investigated the 
distribution of PHI-IR in the guinea pig gallblad- 
der by radioimmunoassay and immunocyto- 
chemistry and examined the effect of PHI on a 
gallbladder smooth muscle preparation in vitro. 
2. MATERIALS AND METHODS 
For radioimmunoassay, the gallbladder, the 
common duct and the cystic duct of 7 
Dunkin-Hartley guinea pigs were obtained after 
the animals were killed by cervical dislocation. The 
tissues were immediately cleaned with water, 
weighed and rapidly placed into polypropylene 
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tubes containing boiling 0.5 mol/l acetic acid 
(-10 ml/g of tissue). Aliquots (10 ~1) of the super- 
natant were measured in duplicate for PHI 
immunoreactivity. 
2.1. Radioimmunoassay 
A full description of the assay has previously 
been reported [2]. The PHI antiserum was pro- 
duced following immunisation with porcine PHI 
conjugated to bovine serum albumin (BSA) with 
glutaraldehyde. The antibody used in this study 
(designated T41) did not cross-react with up to 
100 pmol/tube of all available peptides including 
the structurally related VIP, GIP, glucagon, 
glicentin, secretin, and human pancreatic growth 
hormone releasing factor (BpGRF). Iodination of 
PHI was performed using the Iodogen method and 
purified from unreacted PHI and “‘1 by reverse- 
phase high pressure liquid chromatography 
(HPLC) using isocratic conditions: column: p- 
Bondapak (Waters Associate); mobile phase: 32% 
acetonitrile containing 0.1% trifluoroacetic acid 
(TFA) at a flow rate of 1 ml/min. The assay was 
carried out in phosphate buffer containing 0.01% 
of detergent (Tween 20), 0.3% bovine serum 
albumin (BSA) and 1% aprotinin. 
‘Antibody-bound label’ and ‘free label’ were 
separated by dextran-coated charcoal (4 mg/tube) 
after 5-7 days incubation at 4°C. The inter-assay 
and intra-assay variations were 13 and 5% respec- 
tively. The assay could detect changes of 
0.5 fmol/tube with 95% confidence. 
2.2. Chromatography 
Gallbladder extracts were examined by gel 
permeation and HPLC. For gel permeation 
analysis, samples were applied to a column (0.9 x 
60 cm) of Sephadex G-50 superfine (Pharmacia) 
and eluted at a flow rate of 3.6 ml/h at 4°C with 
phosphate buffer, pH 7.2 containing 0.3% BSA 
and 0.02% Tween 20 (Sigma). The columns were 
precalibrated with dextran blue (M 2 x 106), horse 
heart cytochrome c (M, 12 384) and a trace amount 
of Na’?, which were also added to samples in 
trace amounts as internal markers. In addition, 
porcine PHI standard was chromatographed 
separately so that a comparison of elution position 
could be made. The partition coefficient (&) bet- 
ween the available stationary phase and mobile 
phase was calculated according to [18]. 
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Tissue extracts were also applied onto a Waters 
HPLC system using a pre-packed p-Bondapak Cis 
column (3.9 x 300 mm). Samples were prepared as 
previously described (221. PHI-IR was eluted using 
a gradient of 25-50% acetonitrile/O. 1% TFA. The 
flow rate was 1 ml/min with l-ml fractions col- 
lected for subsequent radioimmunoassay. 
2.3. Immunocytochemistry 
For immunocytochemistry, the gallbladder, the 
common bile duct and the cystic duct were re- 
moved and fixed immediately in 0.4% p- 
benzoquinone (BQS) for 1 h at room temperature 
[ 191. After washing overnight in phosphate- 
buffered saline (PBS) containing 20% sucrose, the 
tissues were made into cryostat blocks by freezing 
in Arcton. lo-pm thick cryostat sections were cut. 
The sections were picked up on poly(L-lysine) 
(PLL)-coated glass slides [20] and allowed to dry 
for 1 h at room temperature. Before immunostain- 
ing the sections were soaked in PBS containing 
0.2% Triton X-100. After washing briefly in PBS, 
a modified indirect immunofluorescence method 
[21] was applied, in which the first layer antiserum 
was repeated. The antiserum to PHI was diluted 
1: 500 in PBS. The controls included preabsorp- 
tion of the first layer antiserum with natural and 
synthetic PHI, the omission of the first layer and 
the use of normal rabbit serum as the first layer. 
2.4. Pharmacology 
Six Dunkin-Hartley guinea pigs were killed by 
cervical dislocation, and the gallbladders were 
removed, opened out and cut into single zig-zag 
strips [23]. The tissues were arranged in cascades 
[24-261 and superfused at 5 ml/min with a Tyrode 
solution bubbled with 95% 02, 5% CO2 at 37°C. 
The sensitivities of the preparations to 
noradrenaline were first demonstrated, and in- 
creasing amounts of PHI and VIP (2-200 pmol) 
were then tested. A mixture of antagonists to 
catecholamines (phenoxybenzamine hydrochloride 
lo-’ g/ml and propranolol hydrochloride 2 x 
10e6 g/ml), histamine (mepyramine maleate 
lo-’ g/ml), 5-hydroxytryptamine (methysergide 
bimaleate 2 x lo-’ g/ml) and acetylcholine 
(hyoscine hydrochloride lo-’ g/ml) was also 
tested. A tension of 1 g was applied to the strips 
and the responses to the peptides were recorded 
isometrically with force transducers (Grass FTO3C) 
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Table 1 
Regional distribution of PHI-IR in the guinea pig 
gallbladder 
PHI-IR pmol/g 
(wet wt of tissue) 
Gallbladder 
Common duct 
Cystic duct 
6.3 f 0.6 
5.0 f 0.7 
7.8 f 1.9 
on a Grass polygraph (Model no. 70). Experiments 
were started after a 60-min equilibration period. 
3. RESULTS 
Table 1 shows the levels of PHI-IR (pmol/g wet 
wt of tissue and quoted as the mean f standard er- 
ror of mean (SE)) in the gallbladder, common and 
cystic duct. PHI-IR was present with similar levels 
(range: 5.0-7.8 pmol/g) in all three areas 
examined. 
Examination of gallbladder extracts by gel 
permeation (fig. 1) shows that they contain a PHI- 
like peptide which co-elutes with porcine PHI (Kav 
0.53). Following HPLC of gallbladder extracts, 
only one major form of PHI-IR (fig.2) was eluted. 
PHI-IR 
(fmol/tube) 
20 
1 
Guinea pig gall bladder 
Kav 
Fig. I. Representative g l chromatographic profile of 
guinea pig gallbladder acid extracts on Sephadex G-50 
superfine. Arrows indicate position of dextran blue (V,), 
cytochrome c (CC) and Nai2’I (V,). A similar 
chromatographic profile was observed with the pure 
porcine PHI standard. 
PHI-IR 
(fmol/tube) 
Guinea 
gall bladder 
PHI 
4 
II_- 
XAcetonitrile 
- -l-50” 
. / 
I 
1 25% 
I 
0 30 60 
Elution volumdml) 
Fig.2. Fractionation of guinea pig gallbladder acid 
extracts on a Waters reverse-phase HPLC system 1221, 
using a linear gradient of 25 to 5Oqo acetonitrile. The 
guinea pig PHI immunoreactivity eluted at 42 ml and 
the porcine PHI standard (arrowed) at 47 ml. 
This PHI-IR was eluted significantly earlier than 
the porcine PHI standard. Recoveries for all 
chromatographic runs were 93 f 7%. 
PHI-immunoreactivity was localised to nerves 
which were distributed throughout the tissue ex- 
amined. In the gallbladder such nerves were more 
abundant in the ganglionic plexus than in other 
Fig;g. Varicose PHM-IR nerve fibres in the smooth 
muscle layer of the gallbladder of guinea pig (x 332). 
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Fig.4. PHM-immunoreactive nerve fibres surrounding 
an arteriole in guinea pig gallbladder wall (x 358). 
regions (fig.3). The PHI-IR nerves formed net- 
works with numerous varicosities and ran in the 
connecting strands between different groups of 
ganglion cells. Such nerve fibres sometimes sur- 
rounded ganglion cells, but the ganglion cells 
50pmol PHI 
-c 
H 
10 min 
I 
2qOpmol PHI 
2fOpmol VIP 
Fig.5. Responses of isolated, superfused guinea pig 
gallbladder preparations totwo doses (SO and 200 pmol) 
of PHI and VIP. All agents were dissolved in Tyrode 
solution. Peptide solutions were applied as indicated by 
arrows. Upward mdvement is contraction and 
downward movement relaxation. 
themselves were not convincingly observed to con- 
tain PHI-immunoreactivity. The muscle layer of 
the gallbladder was innervated by PHI-IR nerves. 
In the cystic and common bile ducts, the PHI-im- 
munoreactivity was mainly distributed in the mus- 
cle layers (fig.4). The frequency of these nerves in 
the muscle layer of the common bile duct gradually 
increased toward the sphincter. In general, the 
distribution pattern of PHI-IR nerves was very 
similar to that of VIP-IR ones reported previously 
[15], but the population of the former was con- 
siderably smaller. All the controls gave negative 
results. 
Porcine PHI induced a dose-dependent relaxa- 
tion of the guinea pig gallbladder which was not 
blocked by any of the inhibitors tested. The onset 
of action was immediate and maxima were 
achieved within 10 min. A comparison of the basal 
relaxant effects of PHI and VIP showed parallel 
concenlration-effect responses (fig.5). 
4. DISCUSSION 
Our results show that guinea pig gallbladder 
contains a significant quantity of PHI-IR which 
has been localised by immunocytochemistry to 
ganglionated and mucosal plexus of the gallblad- 
der. These immunoreactive ganglion cells have a 
similar distribution to those of VIP-containing 
cells, indeed, in the gut the ganglionic cells appear 
to contain both VIP and PHI [3]. In addition, con- 
centrations of PHI-IR quoted here are very similar 
to those reported for VIP-IR [15]. These results, 
therefore, are in agreement with the concept of a 
common precursor for VIP and PHI [27]. Indeed, 
a precursor has recently been identified in a human 
neuroblastoma cell line [28] and in a single vipoma 
[29], which contains the entire sequence of VIP 
and a PHI-like peptide differing by only 2 amino 
acid residues (Arg” replaced by Lys and Ile*’ by 
Met). 
Gel permeation analysis of gallbladder extracts 
suggested that PHI-IR in the guinea pig is of a 
similar size as the porcine PHI standard. However, 
since the guinea pig PHI-IR was eluted at a dif- 
ferent position to porcine PHI following analysis 
by HPLC, it appears that the two sequences vary 
slightly. 
The gallbladder is innervated by excitatory 
cholinergic nerves and inhibitory smooth-muscle 
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relaxant adrenergic nerves 130-341. The existence 
of additional neural control factors was 
demonstrated by the failure to inhibit responses of 
the gallbladder to electrical field stimulation 
[35-371, by adrenergic or cholinergic blockade. 
The presence of biologically active peptides in the 
gallbladder [ 15,381 suggested that these peptides 
may serve to mediate this non-adrenergic, non- 
cholinergic inhibitory response. Some peptides 
have been excluded because they do not cause 
relaxation of the gallbladder, e.g., bombesin [39] 
and CCK-8 [4O]. The possibility that VIP may be 
a mediator was suggested by several observations 
including its presence in the gallbladder [15,41], 
and its ability to relax gallbladder smooth muscle 
independently of adrenergic or cholinergic recep- 
tors [42]. 
A possible physiological action of PHI in the 
gallbladder was first suggested by authors in [17] 
who reported that PHI is capable of decreasing 
basal gallbladder pressure, and that PHI reduces 
bilirubin and bile acid output in man [16]. The 
results here, showing that PHI-IR is present in 
nerves of the gallbladder and that it possesses the 
ability to cause a relaxation of the guinea pig 
gallbladder muscle which is not blocked by many 
antagonists, suggests that PHI may also have a 
physiological role in gallbladder function. 
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